Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Ladenburg Thalmann Downgrades NextCure to Neutral

Ladenburg Thalmann analyst Aydin Huseynov downgrades NextCure (NASDAQ:NXTC) from Buy to Neutral.
byBenzinga Newsdesk
November 4, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

Ladenburg Thalmann analyst Aydin Huseynov downgrades NextCure (NASDAQ:NXTC) from Buy to Neutral.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Teradata Stock Slips After Q4 Results, Weak EPS Guidance

By Erica Kollmann
February 12, 5:58 PM
Teradata reported quarterly earnings of 56 cents per share which beat the analyst consensus estimate of 51 cents by 9.8% and is a 60% increase over earnings of 35 cents per share from the same period last year. The company reported quarterly sales of $457 million, beating the analyst consensus estimate of $456.79 million by 0.05% and representing a 1.11% increase over sales of $452 million year-over-year.

TDC